Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (101-110 of 250) with videos related to

Pageof 25
Sort By:
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Haematologica|January 29, 2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphomaSilvia Montoto, Carol Moreno, Eva Domingo-Doménech, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
British Journal of Haematology|February 18, 2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyMeletios A Dimopoulos, A Keith Stewart, Tamás Masszi, et al.
Haematologica|February 11, 2010
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupAlbert Oriol, Susana Vives, Jesús-María Hernández-Rivas, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
American Journal of Hematology|February 21, 2022
Expression of p53 protein isoforms predicts survival in patients with multiple myelomaElizabeta A Rojas, Luis A Corchete, Cristina De Ramón, et al.
Pageof 25

Showing results (101-110 of 250) with videos related to

Sort By:
Pageof 25
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Haematologica|January 29, 2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphomaSilvia Montoto, Carol Moreno, Eva Domingo-Doménech, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
British Journal of Haematology|February 18, 2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyMeletios A Dimopoulos, A Keith Stewart, Tamás Masszi, et al.
Haematologica|February 11, 2010
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupAlbert Oriol, Susana Vives, Jesús-María Hernández-Rivas, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
American Journal of Hematology|February 21, 2022
Expression of p53 protein isoforms predicts survival in patients with multiple myelomaElizabeta A Rojas, Luis A Corchete, Cristina De Ramón, et al.
Pageof 25